Finally, we conclude that the GAL neuropeptide system might be a promising target for the development of therapeutics which target age-related comorbidities such as anxiety or reduced memory function either as an antagonist (GAL2-R) or agonist (GAL3-R). The gene discussed is GALR2; the disease is Anxiety.